nach oben

CNS Drugs

Erschienen in:

01.11.2009 | Introduction

Toward a New Understanding of Attention-Deficit Hyperactivity Disorder

Advances in Research and Treatment

verfasst von: Thomas J. Spencer

Erschienen in: CNS Drugs | Sonderheft 1/2009

Einloggen, um Zugang zu erhalten

Excerpt

Our understanding of attention-deficit hyperactivity disorder (ADHD), its underlying nature and its treatment have expanded owing to new strides made in basic and clinical research. This supplement comprises four articles, each focusing on an area that has shown significant developments in recent years: (1) the diagnostic and therapeutic challenges presented by patients who have ADHD and comorbid disorders; (2) efficacy, safety and patient selection issues with currently approved pharmacological treatments; (3) advances in defining ADHD neuropathophysiology; and (4) the clinical utility of noradrenergic α₂-receptor agonists for managing ADHD symptoms. …

Busch B, Biederman J, Cohen LG, et al. Correlates of ADHD among children in pediatric and psychiatric clinics. Psychiatr Serv 2002; 53: 1103–11CrossRef

Biederman J, Faraone S, Milberger S, et al. A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Arch Gen Psychiatry 1996; 53: 437–46CrossRef

Biederman J, Faraone SV, Milberger S, et al. Is childhood oppositional defiant disorder a precursor to adolescent conduct disorder? Findings from a four-year follow-up study of children with ADHD. J Am Acad Child Adolesc Psychiatry 1996; 35: 1193–204CrossRef

Spencer TJ. Issues in the management of patients with complex attention-deficit hyperactivity disorder symptoms. CNS Drugs 2009; 23Suppl. 1: 9–20CrossRef

Biederman J, Wilens T, Mick E, et al. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry 1995; 152: 1652–8CrossRef

Biederman J, Petty CR, Dolan C, et al. The long-term longitudinal course of oppositional defiant disorder and conduct disorder in ADHD boys: findings from a controlled 10-year prospective longitudinal follow-up study. Psychol Med 2008; 21: 1–10

Geller D, Donnelly C, Lopez F, et al. Atomoxetine treatment for pediatric patients with attention-deficit/hyperactivity disorder with comorbid anxiety disorder. J Am Acad Child Adolesc Psychiatry 2007; 46: 1119–27CrossRef

Santosh PJ, Baird G, Pityaratstian N, et al. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study. Child Care Health Dev 2006; 32: 575–83CrossRef

Scheffer RE, Kowatch RA, Carmody T, et al. Randomized, placebo-controlled trial of mixed amphetamine salts for symptoms of comorbid ADHD in pediatric bipolar disorder after mood stabilization with divalproex sodium. Am J Psychiatry 2005; 162: 58–64CrossRef

10.

Newcorn JH, Kratochvil CJ, Allen AJ, et al., for the Atomoxetine/Methylphenidate Comparative Study Group. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008; 165: 721–30CrossRef

11.

Adderall XR. Prescribing information. Wayne (PA): Shire Pharmaceuticals, Inc., 2007

12.

Spencer TJ, Sallee FR, Gilbert DL, et al. Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. J Atten Disord 2008; 11: 470–81CrossRef

13.

Concerta. Prescribing information. Mountain View (CA): ALZA Corporation, 2007

14.

Adler LA, Barkley RA, Newcorn JH, et al. Managing ADHD in children, adolescents, and adults with comorbid anxiety. J Clin Psychiatry 2007; 68: 451–62CrossRef

15.

Strattera. Prescribing information. Indianapolis (IN): Eli Lilly & Company, 2007

16.

Scahill L, Pachler M. Treatment of hyperactivity in children with pervasive developmental disorders. J Child Adolesc Psychiatr Nurs 2007; 20: 59–62CrossRef

17.

Wigal SB. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs 2009; 23Suppl. 1: 21–31CrossRef

18.

Arnsten AFT. Toward a new understanding of attention-deficit hyperactivity disorder pathophysiology: an important role for prefrontal cortex dysfunction. CNS Drugs 2009; 23Suppl. 1: 33–41CrossRef

19.

Stuss DT, Knight RT. Principles of frontal lobe function. Oxford University Press, Cary, NC, 2002CrossRef

20.

Arnsten AF. Catecholamine and second messenger influences on prefrontal cortical networks of “representational knowledge”: a rational bridge between genetics and the symptoms of mental illness. Cereb Cortex 2007; 17Suppl. 1: i6–15CrossRef

21.

Bobb AJ, Addington AM, Sidransky E, et al. Support for association between ADHD and two candidate genes: NET1 and DRD1. Am J Med Genet B Neuropsychiatr Genet 2005; 134: 67–72CrossRef

22.

Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57: 1313–23CrossRef

23.

Tahir E, Yazgan Y, Cirakoglu B, et al. Association and linkage of DRD4 and DRD5 with attention deficit hyper-activity disorder (ADHD) in a sample of Turkish children. Mol Psychiatry 2000; 5: 396–404CrossRef

24.

Buschman TJ, Miller EK. Top-down versus bottom-up control of attention in the prefrontal and posterior parietal cortices. Science 2007; 315: 1860–2CrossRef

25.

Knight RT, Staines WR, Swick D, et al. Prefrontal cortex regulates inhibition and excitation in distributed neural networks. Acta Psychol (Amst) 1999; 101: 159–78CrossRef

26.

Scahill L. Alpha-2 Adrenergic agonists in children with inattention, hyperactivity and impulsiveness. CNS Drugs 2009; 23Suppl. 1: 43–49CrossRef

27.

Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2008; 121: e73–84CrossRef

28.

Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1999; 38: 1551–9CrossRef

29.

Hunt RD, Arnsten AF, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995; 34: 50–4CrossRef

30.

Palumbo DR, Sallee FR, Pelham Jr WE, et al. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry 2008; 47: 180–8CrossRef

31.

Scahill L, Chappell PB, Kim YS, et al. A placebo-controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry 2001; 158: 1067–74CrossRef

32.

Daviss WB, Patel NC, Robb AS, et al. Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry 2008; 47: 189–98PubMed

33.

Jakala P, Riekkinen M, Sirvio J, et al. Clonidine, but not guanfacine, impairs choice reaction time performance in young healthy volunteers. Neuropsychopharmacology 1999; 21: 495–502CrossRef

34.

Spiegel R, DeVos JE. Central effects of guanfacine and clonidine during wakefulness and sleep in healthy subjects. Br J Clin Pharmacol 1980; 10Suppl. 1: 165S–8SCrossRef

Titel: Toward a New Understanding of Attention-Deficit Hyperactivity Disorder
Advances in Research and Treatment
verfasst von: Thomas J. Spencer
Publikationsdatum: 01.11.2009
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe Sonderheft 1/2009
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200923000-00002

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2009

Advances in ADHD Treatment: A Focus on the Role of Noradrenergic and Alpha-2a Receptor Modulation

Alpha-2 Adrenergic Agonists in Children with Inattention, Hyperactivity and Impulsiveness

Efficacy and Safety Limitations of Attention-Deficit Hyperactivity Disorder Pharmacotherapy in Children and Adults